Vantictumab, formerly labeled as OMP18R5, represents an novel targeted agent designed for specifically target OPN protein 18R5. This therapy is actively evaluated by the company in anticipated uses in various skeletal conditions, particularly those involving increased skeleton loss. Preclinical studies suggest it is able to efficiently lower osteoc